Evidence map›Paper›PMID 30710873›Full record

ArticleNeuroImage. Clinical2019

Reduced higher dimensional temporal dynamism in neurofibromatosis type 1.

Eva Mennigen, Peter Schuette, Ariana Vajdi, Laura Pacheco, Tena Rosser, Carrie E Bearden

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eva MennigenDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Peter SchuetteDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Ariana VajdiDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Laura PachecoDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Tena RosserChildren's Hospital Los Angeles, Los Angeles, CA, USA; University of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
Carrie E BeardenDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA; Department of Psychology, University of California, Los Angeles, CA, USA. Electronic address: cbearden@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

Human Translational Applications Core (HTA - Core) (7 of 8)PL1MH083271 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BILDER, ROBERT M · 2007 to 2011
$5.8M
Consortium for Neuropsychiatric Phenomics-Coordinating Center (1 of 8)UL1DE019580 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BILDER, ROBERT M · 2008 to 2011
$1.9M
Neurofibromatosis Type I as a Model for Therapeutic NeuroadaptationR34MH089299 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2009 to 2011
$691k
NIDCR NIH HHS UL1 DE019580NIMH NIH HHS PL1 MH083271NIMH NIH HHS R34 MH089299
6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is a common single gene disorder resulting in multi-organ involvement. In addition to physical manifestations such as characteristic pigmentary changes, nerve sheath tumors, and skeletal abnormalities, NF1 is also associated with increased rates of learning disabilities, attention deficit hyperactivity disorder, and autism spectrum disorder. While there are established NF1-related structural brain anomalies, including brain overgrowth and white matter disruptions, little is known regarding patterns of functional connectivity in NF1. Here, we sought to investigate functional network connectivity (FNC) in a well-characterized sample of NF1 participants (n = 30) vs. age- and sex-matched healthy controls (n = 30). We conducted a comprehensive investigation of both static as well as dynamic FNC and meta-state analysis, a novel approach to examine higher-dimensional temporal dynamism of whole-brain connectivity. We found that static FNC of the cognitive control domain is altered in NF1 participants. Specifically, connectivity between anterior cognitive control areas and the cerebellum is decreased, whereas connectivity within the cognitive control domain is increased in NF1 participants relative to healthy controls. These alterations are independent of IQ. Dynamic FNC analysis revealed that NF1 participants spent more time in a state characterized by whole-brain hypoconnectivity relative to healthy controls. However, connectivity strength of dynamic states did not differ between NF1 participants and healthy controls. NF1 participants exhibited also reduced higher-dimensional dynamism of whole-brain connectivity, suggesting that temporal fluctuations of FNC are reduced. Given that similar findings have been observed in individuals with schizophrenia, higher occurrence of hypoconnected dynamic states and reduced temporal dynamism may be more general indicators of global brain dysfunction and not specific to either disorder.

Indexed as

AdolescentAdultCerebellumCerebral CortexChildConnectomeExecutive FunctionFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNerve NetNeurofibromatosis 1Young AdultDynamic functional network connectivityFunctional connectivityGroup independent component analysisMeta-state analysisNeurofibromatosis type 1

Identifiers

PMID30710873
PMCPMC6354288
OpenAlexW2911561261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.